10.01.2013
|
News

Warner Chilcott is now Actavis

On October 1, 2013, Actavis (NYSE: ACT) announced the acquisition of Warner Chilcott plc, creating an $11 billion leading specialty pharmaceutical company with over $3 billion in pro forma sales. The combination capitalizes on the complementary specialty pharmaceuticals strengths and market positions of the two organizations, building a leader in Women’s Health and Urology, as well as a company with important positions in Gastroenterology and Dermatology.